Research & Development World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars

Shire Options Heptares GPCR Target

By R&D Editors | May 10, 2011

 Heptares Therapeutics signed an exclusive option agreement granting Shire Pharmaceuticals an exclusive option, upon completion of certain preclinical studies, to license worldwide development and commercial rights to the Heptares novel adenosine A2A antagonist.

Discovered by Heptares and currently in preclinical development, Adenosine A2A is a G-protein coupled receptor (GPCR) involved in the regulation of dopaminergic pathways in the brain. Inhibition of the A2A receptor has been proved to be clinically effective in treating symptoms of Parkinson’s disease and may offer benefits in additional CNS diseases.

The Heptares A2A program is a new approach to this GPCR target, the company says. Heptares stabilized the A2A receptor using its proprietary StaR technology, determined the receptor’s binding characteristics through Biophysical Mapping, and resolved its 3D crystal structure using X-ray crystallography. This advanced knowledge of the target enabled Heptares scientists to discover new types of chemical structures for inhibiting the A2A receptor.

“We are excited to sign this option agreement with Shire for the development of our novel A2A antagonist, a new agent for treating patients suffering from debilitating CNS diseases,” said Malcolm Weir, chief executive officer of Heptares. “A2A is an important and clinically validated GPCR drug target. Heptares has discovered fundamentally novel chemotypes as the basis for a new and, we believe, superior approach to A2A receptor pharmacology.”

Heptares received an upfront payment and is eligible—upon exercise of the option by Shire—to an option exercise payment, future milestone payments, plus royalties on product sales. Further terms of the agreement were not disclosed.

Release Date: May 9, 2011
Source: Heptares 

Related Articles Read More >

Certara’s COVID vaccine model is focus of Episode 8 of R&D 100 – The Podcast
New dangers in the woods — and the hope that research offers us
PerkinElmer participating at Bio-IT World Conference & Expo
Nalu Medical’s mIPG is focus of Episode 7 of R&D 100 – The Podcast
2021 R&D Global Funding Forecast

Need R&D World news in a minute?

We Deliver!
R&D World Enewsletters get you caught up on all the mission critical news you need in research and development. Sign up today.
Enews Signup

R&D World Digital Issues

February 2020 issue

Browse the most current issue of R&D World and back issues in an easy to use high quality format. Clip, share and download with the leading R& magazine today.

Research & Development World
  • Subscribe to R&D World Magazine
  • Enews Sign Up
  • Contact Us
  • About Us
  • Drug Discovery & Development
  • Pharmaceutical Processing
  • 2022 Global Funding Forecast

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search R&D World

  • Home Page
  • Topics
    • Aerospace
    • Archeology
    • Automotive
    • Biotech
    • Chemistry
    • COVID-19
    • Environment
    • Energy
    • Life Science
    • Material Science
    • R&D Market Pulse
    • R&D Management
    • Physics
  • Technology
    • 3D Printing
    • A.I./Robotics
    • Battery Technology
    • Controlled Environments
      • Cleanrooms
      • Graphene
      • Lasers
      • Regulations/Standards
      • Sensors
    • Imaging
    • Nanotechnology
    • Scientific Computing
      • Big Data
      • HPC/Supercomputing
      • Informatics
      • Security
      • Software
    • Semiconductors
  • 2021 R&D 100 Award Winners
    • R&D 100 Awards
    • 2020 Winners
    • Winner Archive
  • Resources
    • Digital Issues
    • Podcasts
    • Subscribe
  • Global Funding Forecast
  • Webinars